Amchepry: Japan approves stem-cell therapy for Parkinson’s

A Japanese pharmaceutical company has become the first anywhere in the world to market a Parkinson’s therapy in which stem cells are injected directly into patients’ brains. The treatment uses a technique once recognised with a Nobel Prize and is now moving from the laboratory into clinical practice. Many people affected by the condition see it as a glimmer of hope, while specialists urge caution.

What is happening in Japan

Japan’s medicines regulator has approved a product called Amchepry. Its manufacturer, Sumitomo Pharma, is permitted to make and market the treatment. Rather than being a conventional tablet, it is a highly specialised cell therapy.

For the first time, a Parkinson’s treatment has been approved in which stem cells grown in the laboratory are specifically converted into nerve cells and then transplanted into the brain.

The authorisation rests on data from a small study involving seven patients aged between 50 and 69. Each participant was given injections of several million cells into particular brain regions that are crucial for controlling movement.

Researchers monitored their progress for two years. Four of the seven participants reported a marked reduction in symptoms, and no serious adverse effects were observed. For a chronic condition previously treated only with symptom-relieving medicines, this represents a notable development.

Parkinson’s: when the brain loses control

Parkinson’s is among the most common neurological diseases in later life. Estimates suggest that it affects several million people worldwide, and the number of people living with it has also been rising in Germany for years.

Typical features include:

• tremor at rest, especially in the hands and arms
• rigid muscles and slowed movement
• an unsteady gait, falls and freezing of steps
• later, often sleep difficulties, depression and cognitive decline

At the heart of the disease is a particular type of brain cell: dopaminergic nerve cells. These produce dopamine, a messenger substance that helps movements remain smooth and controlled. As these cells gradually die, the delicately balanced system breaks down. Tablets such as L-Dopa can replace some of the missing dopamine, but their effectiveness and tolerability often diminish over time.

Stem cells: what do they actually involve?

Understanding the new approach requires a look at the basics. Stem cells are regarded as the body’s raw material. They have not yet been assigned a specific role and can develop into different types of tissue.

The main types of stem cell

Type	Origin	Capabilities
Unipotent	specific tissues in adulthood	only one cell type, but capable of self-renewal
Multipotent	foetus and adults, for example bone marrow	several related cell types, such as blood cells
Pluripotent	early embryos or reprogrammed cells	more than 200 cell types from almost all tissues
Totipotent	fertilised egg during its first few days	can form a complete organism

For a long time, the most powerful stem cells were considered to come from very early embryos, raising major ethical conflicts. This is precisely where the Nobel Prize-winning technique comes in.

From a skin cell back to an “all-purpose cell”

In 2006, Japanese researcher Shinya Yamanaka developed a method that transformed stem-cell research. He demonstrated that ordinary specialised body cells, such as skin cells, could be returned to an earlier state with the help of certain genetic factors.

These so-called iPS cells, or induced pluripotent stem cells:

• are taken from adult tissue, such as blood or skin
• are pluripotent and therefore exceptionally adaptable
• avoid the use of embryos and, with it, many ethical conflicts

Using iPS cells, researchers can grow new tissues in the laboratory almost to a blueprint: heart muscle, liver cells or dopaminergic nerve cells, which are lost in Parkinson’s. This is the strategy behind the Japanese product that has now been approved.

Why this new Parkinson’s therapy is so distinctive

As early as the 1980s, teams attempted to replace missing nerve cells in the brains of people with Parkinson’s by using tissue from aborted foetuses. Some patients regained mobility, in some cases for many years. Others developed severe uncontrolled movements or saw no benefit at all.

The early attempts suffered from inconsistent quality of cell material, donor sources that were scarcely controllable and profound ethical problems.

The iPS technique changes these conditions:

• Cells can be produced in a standardised way in the laboratory.
• Their conversion into dopaminergic nerve cells follows clearly defined protocols.
• There is no longer a reliance on scarce and controversial donations of foetal tissue.

In the Japanese approach, the prepared cells are injected into areas of the brain where particularly large numbers of dopaminergic neurons have been lost. There, they are intended to connect with surrounding cells, produce dopamine and thereby stabilise the movement programme.

How well does the treatment really work?

The central question remains whether this is a genuine breakthrough or a very early source of hope. The available data are encouraging, but limited.

The results so far at a glance:

• seven patients treated
• 5 to 10 million cells delivered directly into the brain per person
• observation period: two years
• four people experienced noticeable symptom improvement
• no serious unexpected adverse effects during this period

For a chronic illness that often progresses over decades, two years is a short period. Many benefits, as well as risks, may only become evident later.

Fast-track approval: benefit or risk?

Japan operates under a separate regulatory framework for regenerative medicine. Therapies based on tissue or cell replacement can receive accelerated approval there. Companies may offer their product for up to seven years while additional data are gathered in parallel.

Sumitomo Pharma used precisely this route for Amchepry. Critics warn that the drive for innovation could shorten the patience required for lengthy safety studies. A particular concern is uncontrolled cell growth, meaning tumours that can arise from stem cells in rare cases.

Many specialists regard the clearance as a bold move with wider significance – and, at the same time, a major real-time experiment involving actual patients.

Japan’s regulator, by contrast, stresses that it examined the data carefully and will rigorously assess every new piece of information. Should problems emerge, the approval could be withdrawn or restricted.

Stem-cell medicine far beyond Parkinson’s

Amchepry is not the only novel treatment benefiting from Japan’s fast-track route. Another company, Cuorips, has been authorised to use a product for heart failure. In this case, specialised cells are intended to strengthen damaged heart muscle and improve pumping capacity.

This demonstrates that iPS-based therapies are not aimed solely at the brain. In principle, they could be considered for numerous degenerative conditions in which lost tissue is replaced or stabilised, from chronic heart failure and retinal damage to certain forms of diabetes.

What this could mean for patients

For people affected in Europe and Germany, the new treatment is not yet an available option but a signal. Given the complexity of the procedure and strict regulation, Amchepry is likely to be available only at selected centres in Japan for the foreseeable future.

Even so, the outlook is changing:

• Clinicians will gain practical data on benefits and risks.
• Regulators in the EU and US can use these experiences to adapt their own frameworks.
• Research teams will gain momentum for further studies involving larger patient groups.

For people newly diagnosed with Parkinson’s, standard treatment with medicines, exercise training and, in some cases, deep brain stimulation remains the core of care. At the same time, the likelihood is growing that additional options could become available in a few years, acting much more deeply on the disease process.

Opportunities, limitations and unanswered questions

Stem-cell therapies may sound like science fiction, but they are now routine laboratory work and, in Japan, have for the first time become a regular part of patient care. That prompts both hope and anxiety.

Potential benefits include the targeted replacement of lost cells, less dependence on treatments that merely address symptoms and more individualised therapies. Against this stand high costs, complex procedures, the small number of patients studied so far and uncertainty about long-term consequences.

There is another consideration: not every form of Parkinson’s follows the same course. Genetic variants, co-existing conditions, age and previous experience with medicines all strongly affect how well a patient might respond to stem-cell therapy. Future studies must establish who will truly benefit from the procedure, and who will not.

For patients and their families, a level-headed view is worthwhile. Japan’s approval shows that the vision of replacing cells in the brain is becoming tangible. At the same time, Parkinson’s remains a complex disease that can scarcely be “repaired” through a single procedure. The coming years will reveal whether Japan’s bold step proves to be a medical milestone or an overly optimistic fast start.